1. Home
  2. GOVX vs UTSI Comparison

GOVX vs UTSI Comparison

Compare GOVX & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOVX
  • UTSI
  • Stock Information
  • Founded
  • GOVX 2001
  • UTSI 1991
  • Country
  • GOVX United States
  • UTSI China
  • Employees
  • GOVX N/A
  • UTSI N/A
  • Industry
  • GOVX Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • GOVX Health Care
  • UTSI Telecommunications
  • Exchange
  • GOVX Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • GOVX 23.8M
  • UTSI 25.4M
  • IPO Year
  • GOVX N/A
  • UTSI 2000
  • Fundamental
  • Price
  • GOVX $2.26
  • UTSI $2.45
  • Analyst Decision
  • GOVX Strong Buy
  • UTSI
  • Analyst Count
  • GOVX 5
  • UTSI 0
  • Target Price
  • GOVX $14.20
  • UTSI N/A
  • AVG Volume (30 Days)
  • GOVX 715.7K
  • UTSI 8.3K
  • Earning Date
  • GOVX 11-12-2024
  • UTSI 09-05-2024
  • Dividend Yield
  • GOVX N/A
  • UTSI N/A
  • EPS Growth
  • GOVX N/A
  • UTSI N/A
  • EPS
  • GOVX N/A
  • UTSI N/A
  • Revenue
  • GOVX $3,090,161.00
  • UTSI $14,958,000.00
  • Revenue This Year
  • GOVX N/A
  • UTSI N/A
  • Revenue Next Year
  • GOVX $150.51
  • UTSI N/A
  • P/E Ratio
  • GOVX N/A
  • UTSI N/A
  • Revenue Growth
  • GOVX N/A
  • UTSI 14.41
  • 52 Week Low
  • GOVX $1.09
  • UTSI $2.20
  • 52 Week High
  • GOVX $11.18
  • UTSI $3.54
  • Technical
  • Relative Strength Index (RSI)
  • GOVX 44.80
  • UTSI 36.82
  • Support Level
  • GOVX $2.17
  • UTSI $2.57
  • Resistance Level
  • GOVX $2.50
  • UTSI $2.80
  • Average True Range (ATR)
  • GOVX 0.17
  • UTSI 0.15
  • MACD
  • GOVX -0.04
  • UTSI -0.03
  • Stochastic Oscillator
  • GOVX 18.33
  • UTSI 0.00

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.

Share on Social Networks: